Ozmosi | Octanoic acid Drug Profile

Product Description

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Australia | Chile | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: INFAI
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: Hypotension|Exocrine Pancreatic Insufficiency

Phase 2: Essential Tremor

Phase 1: Essential Tremor|Gastroparesis|Fatty Liver|Type 2 Diabetes|Obesity

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
ACTRN12616000702415	AACI	N/A	Completed	Type 2 Diabetes\|Malnutrition	2017-01-31	2024-08-29	Treatments
NCT03467737	NCT03467737	N/A	Completed	Child Nutrition Disorders\|Malnutrition	2014-12-31	2019-03-22	Treatments
ACTRN12611000706976	ACTRN12611000706976	N/A	Completed	Obesity	2012-12-10	2024-11-19	Treatments
ACTRN12609000542291	ACTRN12609000542291	N/A	Completed	Obesity\|Type 1 Diabetes\|Type 2 Diabetes	2008-12-12	2024-08-29	Treatments
ACTRN12610000112066	ACTRN12610000112066	N/A	Completed	Overweight	None	2024-04-03	Treatments
ACTRN12618001764224	ACTRN12618001764224	P1	Completed	Type 2 Diabetes\|Obesity	2018-02-01	2024-08-29	Treatments
NCT02602158	13CTriOBT	P1	Completed	Fatty Liver\|Gastroparesis	2016-04-01	2019-03-20	Treatments
NCT01468948	12-N-0024	P1	Completed	Essential Tremor	2012-07-18	2019-03-19
NCT01864525	1R03DC012429-01A1	P2	Completed	Essential Tremor	2016-12-22	2019-03-19	Treatments
2011-002782-38	13COBT	P2	Active, not recruiting	Unknown	2013-01-06	2022-03-13	Treatments
NCT00848172	09-N-0084	P2	Completed	Essential Tremor	2010-11-01	2019-03-18	Treatments
ACTRN12617000349347	PERT	P4	Not yet recruiting	Hypotension\|Exocrine Pancreatic Insufficiency	2018-06-01	2024-08-29	Treatments

Recent News Events

Date	Type	Title
05/12/2024	PubMed	Characterization and drug solubilization of arginine-based ionic liquids - Impact of counterions and stoichiometry.
05/03/2024	PubMed	Chemical Characterization of Terpene-Based Hydrophobic Eutectic Solvents and Their Application for Pb(II) Complexation during Solvent Extraction Procedure.
05/01/2024	PubMed	Fabrication of Human Milk Fat Substitute: Based on the Similarity Evaluation Model and Computer Software.
07/20/2023	News Article	Caprylic Acid Market Size Predictions suggest a rise of 13.8% CAGR, to reach value of USD 17.3 Billion by 2032
01/10/2022	News Article	Cetearyl Ethylhexanoate Market (2021-2025) Explore Key strategic and Developments by Key Players, Application, Type
01/10/2022	News Article	Cetearyl Ethylhexanoate Market 2021 In-depth Assessment, Key Trend, Industry Drivers, Future Roadmap by 2025
04/11/2021	News Article	Cetearyl Ethylhexanoate Market Expected to Expand at a High CAGR By End of 2025

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Octanoic acid

Alternative Names: octanoic acid Clinical Status: Inactive Latest Update: 2024-09-19 Latest Update Note: Clinical Trial Update